Source: PMLiVE

SOVALDI: Could Gilead face early Sovaldi generics in Europe?

EU patent protection for the hepatitis C virus drug will end in 2024

Read full article »

SOVALDI's Competitors | SOVALDI's News | SOVALDI's Financials

Followers on Owler

1

Est. Annual Revenue

$5.0-25M

Est. Employees

25-100

CEO

Update CEO

CEO Approval Rating

- -/100

SOVALDI develops and commercializes drugs for hepatitis C treatment.